Shots:

• Viatris' interchangeable biosimilar Semglee (insulin glargine-yfgn) injection will be added in Express Scripts as a preferred insulin brand on its NPF for diabetic patients in the US
• Biocon and Viatris have jointly developed Semglee. Additionally, Viatris will commercialize two interchangeable biosimilar insulin glargine injection at the end of 2021 i.e., Semglee & Insulin to improve patients access with diabetes. Additionally, formulary coverage of Semglee on its NPF initiates in Jan'22
• Both products will be available in pen and vial presentations and are interchangeable for the reference brand, Lantus

to­ / article | Ref: ViatrisImage: Viatris